Head-To-Head Contrast: Agenus (AGEN) vs. The Competition
Agenus (NASDAQ: AGEN) is one of 185 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its rivals? We will compare Agenus to related companies based on the strength of its analyst recommendations, valuation, risk, profitability, earnings, institutional ownership and dividends.
This table compares Agenus and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Agenus has a beta of 2.11, suggesting that its share price is 111% more volatile than the S&P 500. Comparatively, Agenus’ rivals have a beta of 1.53, suggesting that their average share price is 53% more volatile than the S&P 500.
Valuation and Earnings
This table compares Agenus and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Agenus||$22.57 million||-$126.99 million||-2.90|
|Agenus Competitors||$217.36 million||-$39.57 million||-62.08|
Agenus’ rivals have higher revenue and earnings than Agenus. Agenus is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
37.9% of Agenus shares are held by institutional investors. Comparatively, 49.9% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 7.9% of Agenus shares are held by insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This is a breakdown of recent ratings and target prices for Agenus and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Agenus currently has a consensus price target of $6.33, suggesting a potential upside of 86.82%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.46%. Given Agenus’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Agenus is more favorable than its rivals.
Agenus rivals beat Agenus on 7 of the 13 factors compared.
Agenus Company Profile
Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company’s discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company’s vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with Analyst Ratings Network's FREE daily email newsletter.